United Therapeutics Announces World's First Bioengineered External Liver Treatment in Clinical Study
United Therapeutics Corporation (NASDAQ:UTHR) is one of the most undervalued US stocks according to analysts.
United Therapeutics Corp (UTHR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,675,000 | $824,622,250 | -4% | 12.87% |
| 2. | Renaissance Technologies Jim Simons | 2,106,992 | $649,522,424 | +1% | 0.98% |
| 3. | AQR Capital Management Cliff Asness | 908,448 | $273,306,521 | -7% | 0.28% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 398,230 | $122,762,362 | -27% | 0.1% |
| 5. | Deerfield Management James E. Flynn | 275,226 | $84,843,919 | 1.68% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.83 | 4 | $331.32 | 1,684 | 2019-06-10 | Filing | |
| $114.06 | 6 | $684.36 | 1,686 | 2018-04-20 | Filing | |
| $126.20 | 5 | $631.00 | 1,685 | 2017-11-20 | Filing | |
| $128.35 | 3 | $385.05 | 1,686 | 2017-07-28 | Filing | |
| $130.24 | 3 | $390.72 | 1,683 | 2017-07-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $288.80 | 100 | $28,880.00 | 36,781 | 2025-06-26 | Filing | |
| $287.92 | 1,150 | $331,110.30 | 36,881 | 2025-06-26 | Filing | |
| $287.21 | 2,334 | $670,353.74 | 38,031 | 2025-06-26 | Filing | |
| $286.13 | 939 | $268,675.51 | 40,365 | 2025-06-26 | Filing | |
| $285.01 | 3,940 | $1,122,929.55 | 41,304 | 2025-06-26 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 249 | $71,550 | 0.01% | |
| 2. | 5 | $1,437 | 0% |
News See All
11 Most Undervalued US Stocks According to Analysts
On June 26, Noah Blackstein, Dynamic Funds senior portfolio manager, joined CNBC's 'Squawk Box' to discuss the current market and economic conditions.
15 Best Stocks to Buy According to Jim Simons' Renaissance Technologies
Even after his passing in 2024, billionaire investor and mathematician Jim Simons remains known as the "Quant King" of hedge funds due to the extraordinary success of Renaissance Technologies, his quantitative...
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript April 30, 2025United Therapeutics Corporation beats earnings expectations.
7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
10 Best Healthcare Stocks For Long-Term Investment
In the US, healthcare expenditures and costs have been increasing. According to the Centers for Medicare & Medicaid Services, US healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript February 26, 2025United Therapeutics Corporation beats earnings expectations.
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
12 Cheap Healthcare Stocks to Buy Heading into 2025
Investing in healthcare equities is typically seen as protective during recessionary times.
Billionaire Hedge Funds
